Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Status: Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 25 Jul 2018
Price : $35 *
At a glance
- Drugs Deferasirox (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 12 Sep 2014 New trial record